(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/178768 A1

(51) International Patent Classification:
A61K 31/4045 (2006.01) *A61K 9/00* (2006.01)
A61K 45/06 (2006.01) *A61P 13/12* (2006.01)

(21) International Application Number:
PCT/US2021/021037

(22) International Filing Date:
05 March 2021 (05.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/986,096 06 March 2020 (06.03.2020) US

(71) Applicant: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: **EGBUNA, Ifeatu**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **HARE, Brian J.**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **KRUG, Alexander Wolfgang**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **MALLALIEU, Navita**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **WU, Shu-Pei**; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(74) Agent: **MCDONELL, Leslie A.**; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS

(57) Abstract: This application describes methods of inhibiting APOL1 and treating APOL1-mediated diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. Compound I The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.



Compound I

WO 2021/178768 A1